Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-05-14

FDA Approved: EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Laurus Labs Limited)

View source ↗

Summary

FDA approved Laurus Labs' generic fixed-dose combination efavirenz, lamivudine, and tenofovir disoproxil fumarate for HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz, lamivudine and tenofovir disoproxil fumarate)

Snippet

ORIG AP for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE)